Health inspectors will on Saturday begin issuing citations and fines to New York City fast-food chain restaurants that fail to post calorie counts next to the prices on their menus.

The new rule, allowing a two-month grace period, took effect in May. It marks the first time a U.S. city has launched an anti-obesity campaign. It requires restaurants that have 15 or more nationwide outlets to post calorie information beside their prices

A new drug could potentially save the lives of thousands of prostate cancer sufferers, new studies have shown, while eliminating the need for damaging chemotherapy and radiotherapy.

The drug, abiraterone, works by blocking the hormones which fuel the cancer and a human trial has shown that it can shrink tumors in up to 80 percent of cases. The technique could also be effective on other tumors, such as breast and bowel cancers, Britain's Daily Mail reported

Most Canadian citizens are likely to survive the often fatal disease of cancer because of the country's accessible and reliable health care system, according to a Concord study.

The study, which will appear in the August issue of The Lancet Oncology, revealed that Canada ranked second in patient survival for breast cancer, third for prostate cancer in men and for colorectal cancer in women, and sixth for colorectal cancer in men

Older women who either sleep too much or too little are at a greater risk of suffering from stroke, a new study shows. Researchers found that habitual sleep patterns in postmenopausal women could be important in determining the risk of ischemic stroke.

Researchers from Albert Einstein College of Medicine in New York City studied 93,676 postmenopausal women and found that those who regularly slept nine hours or more were 70 percent more likely to have an ischemic stroke, compared with women who slept seven hours a night

A human trial of a large-scale experimental AIDS vaccine has been cancelled following advice by a top scientist that it was unlikely to give useful results, the National Institutes of Health (NIH) said Thursday.

The vaccine trial, similar to a failed Merck and Co. product, was developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease. In a study called PAVE 100, the agency planned to include 2,400 men in the United States